3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
120
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Recurrence
17
Burkitt Lymphoma
15
Lymphoma, Large B-Cell, Diffuse
8
Neoplasms, Plasma Cell
7
Immunoglobulin Light-chain Amyloidosis
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms
6
Leukemia, Biphenotypic, Acute
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma
5
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Lung Neoplasms
4
Leukemia
4
Waldenstrom Macroglobulinemia
3
Nausea
3
Lymphoma, B-Cell
3
Brain Neoplasms
3
Smoldering Multiple Myeloma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Paraproteinemias
2
Ovarian Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Down Syndrome
2
Interventions
Prednisone
5
Docetaxel
4
niraparib
2
enzalutamide
2
darolutamide
2
Pluvicto
2
Abiraterone Acetate
2
olaparib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
cabazitaxel
1
abiraterone
1
Rosuvastatin Calcium
1
Pioglitazone
1
Omeprazole
1
JNJ-64619178
1
JNJ-64264681
1
Dexamethasone
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
Dexamethasone
×
90 days
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled